Status:
COMPLETED
Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity
Lead Sponsor:
Duke University
Conditions:
Stroke
Eligibility:
All Genders
3-18 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess prospectively the efficacy of hydroxyurea therapy in the setting of cerebrovascular disease, manifest as conditional or abnormal transcranial doppler ultrasonogr...
Detailed Description
The purpose of this study is to assess prospectively the efficacy of hydroxyurea therapy in the setting of cerebrovascular disease, manifest as conditional or abnormal transcranial doppler ultrasonogr...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Children with Sickle Cell Anemia
- Aged 3 to 18 years
- Confirmed TCD velocity greater than or equal to 140cm/sec
- Negative serum pregnancy test for subjects of childbearing potential
- Decline transfusions (for subjects with TCD velocity greater than or equal to 200 cm/sec)
Exclusion
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00402480
Start Date
April 1 2003
End Date
March 1 2006
Last Update
June 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710